
NYSE:PFE
This summary was created by AI, based on 23 opinions in the last 12 months.
Pfizer Inc. (PFE) is currently facing challenges following its pandemic-driven peak during which it surged due to COVID-19 vaccine sales. Experts have pointed out a lack of earnings momentum and concerns over a patent cliff, as key drugs have come off patent and the company needs to innovate to develop new blockbuster drugs. Despite these challenges, many analysts emphasize the attractive dividend yield, which remains around 6-8%. The company is pivoting towards growth areas such as obesity and oncology, and while there's a general belief that PFE is under pressure, patience from investors could yield positive results. Several insights indicate that while it may not attract immediate growth, the company’s efforts in acquisitions and drug development could eventually pay off, given time.
Look at the 30-year chart. Stock's around the same price today as then, despite the 10s of billions in acquisitions over the years. Partly speaks to industry conditions, partly to lack of blockbuster drugs. Dividend secure. Terrible investment for decades. Yield is 6%.
At a pivotal point on the technical charts. Based down early this month and just moved up to 200-day MA, which is falling. If it can break that, it's positive for the stock. Really great dividend of 5.76% is fairly safe. If you're patient, it's OK. Stronger growth companies in healthcare, such as weight loss and diabetes. 8% growth rate.
US dividend stocks don't usually pay nearly as much as Canadian ones. If he's looking for income, there are tax and other advantages to owning Canadian dividend stocks, especially in non-registered portfolios.
Underperformer in the sector. Not in a growth area, which is weight loss right now. So he'd probably look at LLY and NVO. Those pipelines are probably going to be fairly robust.
It is down 60% from its peak and trading at 10X forward earnings with a 6% dividend yield, It took the windfall cash from the Covid vaccines, etc. and re-invested in new growth areas such as cancer, diabetic and weight loss treatments/ drugs., It is out of favour and there is potential for growth.
Buy 11 Hold 15 Sell 0
Industry, overall, is fairly mature. Challenging to get drugs approved. Pharma companies are struggling to grow, dealing with patent cliffs. Flipside is generating good cashflows. Very attractive for income, but don't own it for share price performance, since growth is challenged. Yield is 6.5%, safe.
Strong dividend yield. Will continue to own shares. Weakness after the Covid-19 expected, but large decrease a surprise. However, strong pipeline of new drugs, and well known brand name. Expecting stock price to appreciate in the future.